Common Contracts
2 similar Exclusive License Agreement contracts by Affinia Therapeutics Inc.
EXCLUSIVE LICENSE AGREEMENT BETWEEN LONZA HOUSTON, INC. AND MASSACHUSETTS EYE AND EAR INFIRMARY AND THE SCHEPENS EYE RESEARCH INSTITUTE, INC. AND TDTX, INC. September 9, 2019Exclusive License Agreement • January 4th, 2022 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”), effective as of September 9, 2019 (“Effective Date”), is made between Lonza Houston, Inc., a Delaware corporation having a principal place of business at 14905 Kirby Drive, Houston, Texas 77047, United States, (“Lonza”) and Massachusetts Eye and Ear Infirmary, a not-for-profit Massachusetts corporation, having its principal place of business at 243 Charles Street, Boston, MA 02114, and The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having its principal place of business at 20 Staniford Street, Boston, MA 02114 (collectively “MEE”) (Lanza and MEE are collectively referred to herein as “Licensor(s)”), and TDTx Inc., a Delaware corporation having a principal place of business at One Broadway, 14th Floor, Kendall Square, Cambridge, MA 02142 (“TDTx” or “Licensee”). Lonza, MEE, and TDTx shall hereinafter collectively be referred to as the “Parties” and each, individually, as a “Party”.
EXCLUSIVE LICENSE AGREEMENT BETWEEN LONZA HOUSTON, INC. AND MASSACHUSETTS EYE AND EAR INFIRMARY AND THE SCHEPENS EYE RESEARCH INSTITUTE, INC. AND TDTX, INC. September 9, 2019Exclusive License Agreement • November 24th, 2021 • Affinia Therapeutics Inc. • Biological products, (no disgnostic substances)
THIS EXCLUSIVE LICENSE AGREEMENT (“Agreement”), effective as of September 9, 2019 (“Effective Date”), is made between Lonza Houston, Inc., a Delaware corporation having a principal place of business at 14905 Kirby Drive, Houston, Texas 77047, United States, (“Lonza”) and Massachusetts Eye and Ear Infirmary, a not-for-profit Massachusetts corporation, having its principal place of business at 243 Charles Street, Boston, MA 02114, and The Schepens Eye Research Institute, Inc., a not-for-profit Massachusetts corporation, having its principal place of business at 20 Staniford Street, Boston, MA 02114 (collectively “MEE”) (Lanza and MEE are collectively referred to herein as “Licensor(s)”), and TDTx Inc., a Delaware corporation having a principal place of business at One Broadway, 14th Floor, Kendall Square, Cambridge, MA 02142 (“TDTx” or “Licensee”). Lonza, MEE, and TDTx shall hereinafter collectively be referred to as the “Parties” and each, individually, as a “Party”.
